EFNB2 and neoplasm: Additionally, our data show that vascular ephrinB2 loss combined with RT enhanced systemic CD4+ and CD8 + T cell activation, trended towards decreased Treg immunosuppression, and reduced CD4 + T cell entry into the tumor.